Xencor

XNCR · NASDAQ

$24.94+$1.75 (+7.55%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $23.19

Latest news

Press releaseOct 19, 7:01 AM ETBusiness Wire
Xencor to Host Webcast to Discuss Results From the Phase 1 Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
Press releaseAug 5, 4:01 PM ETBusiness Wire
Xencor Reports Second Quarter 2026 Financial Results
Press releaseJul 29, 4:01 PM ETBusiness Wire
Xencor to Receive $105 Million From Alexion to Resolve Ultomiris® U.S. Royalty Matter
NewsJul 20, 10:08 AM ETAvi Kapoor
AMC Entertainment, IREN, Hut 8 And Other Big Stocks Moving Higher On Monday
Press releaseJul 17, 9:11 AM ETBusiness Wire
Xencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
Press releaseJul 6, 11:19 AM ETPRNewswire
A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs
Press releaseMay 18, 8:34 AM ETBusiness Wire
The Biology Came First.
NewsMay 6, 5:03 PM ET
Earnings Scheduled For May 6, 2026
Press releaseMay 6, 4:01 PM ETBusiness Wire
Xencor Reports First Quarter 2026 Financial Results
Press releaseMay 4, 8:01 AM ETBusiness Wire
Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW
Press releaseMar 4, 4:01 PM ETBusiness Wire
Xencor Announces Change to Ultomiris® Royalty Revenue Forecast
Press releaseFeb 25, 4:01 PM ETBusiness Wire
Xencor Reports Fourth Quarter and Full Year 2025 Financial Results
Press releaseFeb 23, 4:01 PM ETBusiness Wire
Xencor to Participate at Upcoming Investor Conferences
NewsFeb 17, 4:06 PM ET
12 Health Care Stocks Moving In Tuesday's After-Market Session
Press releaseJan 8, 8:01 AM ETBusiness Wire
Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones
Press releaseDec 9, 7:00 AM ETBusiness Wire
Xencor Announces Extension of U.S. Patent Term on Certain Xtend™ Antibodies
Press releaseNov 10, 4:01 PM ETBusiness Wire
Xencor to Participate at Upcoming Investor Conferences
Press releaseNov 5, 4:01 PM ETBusiness Wire
Xencor Reports Third Quarter 2025 Financial Results
Press releaseOct 24, 12:30 PM ETBusiness Wire
Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma
Press releaseOct 21, 8:01 AM ETBusiness Wire
Xencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
Press releaseOct 17, 9:50 AM ETPRNewswire
Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation
Press releaseOct 14, 12:45 PM ETBusiness Wire
Xencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
NewsSep 2, 5:00 PM ET
Beyond The Numbers: 4 Analysts Discuss Xencor Stock
Press releaseAug 27, 4:01 PM ETBusiness Wire
Xencor to Participate at Upcoming Investor Conferences
Press releaseAug 6, 4:01 PM ETBusiness Wire
Xencor Reports Second Quarter 2025 Financial Results
Press releaseJul 31, 4:01 PM ETBusiness Wire
Xencor Appoints Raymond Deshaies, Ph.D., to Board of Directors
NewsMay 9, 5:06 PM ET
12 Health Care Stocks Moving In Friday's After-Market Session
Press releaseMay 7, 4:01 PM ETBusiness Wire
Xencor Reports First Quarter 2025 Financial Results
Press releaseApr 29, 4:01 PM ETBusiness Wire
Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease
Press releaseMar 13, 4:01 PM ETBusiness Wire
Xencor Appoints Todd Simpson to Board of Directors
NewsFeb 6, 7:05 AM ET
12 Health Care Stocks Moving In Thursday's Pre-Market Session
NewsDec 2, 7:00 AM ET
Critical Insights From Xencor Analyst Ratings: What You Need To Know
NewsSep 26, 11:01 AM ET
Xencor Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
NewsJul 31, 3:01 PM ET
Decoding 5 Analyst Evaluations For Xencor

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Xencor to Host Webcast to Discuss Results From the Phase 1 Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma

Xencor Reports Second Quarter 2026 Financial Results

Xencor to Receive $105 Million From Alexion to Resolve Ultomiris® U.S. Royalty Matter

AMC Entertainment, IREN, Hut 8 And Other Big Stocks Moving Higher On Monday

Xencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma

A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs

The Biology Came First.

Earnings Scheduled For May 6, 2026

Xencor Reports First Quarter 2026 Financial Results

Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW

Xencor Announces Change to Ultomiris® Royalty Revenue Forecast

Xencor Reports Fourth Quarter and Full Year 2025 Financial Results

Xencor to Participate at Upcoming Investor Conferences

12 Health Care Stocks Moving In Tuesday's After-Market Session

Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones

Xencor Announces Extension of U.S. Patent Term on Certain Xtend™ Antibodies

Xencor to Participate at Upcoming Investor Conferences

Xencor Reports Third Quarter 2025 Financial Results

Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma

Xencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma

Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation

Xencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Beyond The Numbers: 4 Analysts Discuss Xencor Stock

Xencor to Participate at Upcoming Investor Conferences

Xencor Reports Second Quarter 2025 Financial Results

Xencor Appoints Raymond Deshaies, Ph.D., to Board of Directors

12 Health Care Stocks Moving In Friday's After-Market Session

Xencor Reports First Quarter 2025 Financial Results

Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease

Xencor Appoints Todd Simpson to Board of Directors

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Critical Insights From Xencor Analyst Ratings: What You Need To Know

Xencor Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

Decoding 5 Analyst Evaluations For Xencor